StockData
Fate Therapeutics Inc logo

Fate Therapeutics Inc (FATE) stock

FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3014% below fair value
$1.02−0.12 (-10.53%)

Close on Nov 17, 2026Market cap $122.22MP/E –Yield –

Fate Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Fate Therapeutics's price to book ratio was 1.2× on Nov 11, 2026, against 0.6× a year earlier. Over the last 5 years it ranged from 0.3× to 7.6×, with a median of 1.1×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.2×+0.7
2025Dec 31, 20250.5×−0.0
2024Dec 31, 20240.5×−0.4
2023Dec 29, 20230.9×−1.0
2022Dec 30, 20221.9×−5.7
2021Dec 31, 20217.6×−11.0
2020Dec 31, 202018.6×+13.1
2019Dec 31, 20195.5×+0.7
2018Dec 31, 20184.8×−0.8
2017Dec 29, 20175.5×+2.2
2016Dec 30, 20163.4×+1.2
2015Dec 31, 20152.2×−0.9
2014Dec 31, 20143.1×–

More Fate Therapeutics figures

See a number that looks wrong?